Sequenom Plans Sample-Prep Automation, Increased Multiplexing to Double MaterniT21 Capacity | GenomeWeb

This story was originally published May 4.

Sequenom said last week that it is planning to increase multiplexing and automate sample prep for its MaterniT21 Plus test during the second half of the year, which will double its yearly capacity to 200,000 tests.

Additionally, it reported during a conference call to discuss its first-quarter earnings that the uptake of MaterniT21 Plus has been increasing weekly, and as of the last week of April, its accession run rate was more than 45,000 tests per year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.